- Raw materials
- Antibacterials
- Glycopeptides
- Teicoplanin
Filters
Custom request?
Type
Production region
Qualifications
Country of origin
Teicoplanin API Manufacturers & Suppliers
8 verified results
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Commercial-scale Suppliers
Employees: 50+
All certificates
All certificates
All certificates
All certificates
All certificates
All certificates
All certificates
All certificates
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Teicoplanin | CAS No: 61036-62-2 | GMP-certified suppliers
A medication that treats systemic bacterial infections caused by susceptible Gram-positive microorganisms, offering targeted anti-infective benefits for healthcare applications.
Therapeutic categories
Primary indications
- For the treatment of bacterial infections caused by susceptible microorganisms
Product Snapshot
- Teicoplanin is available primarily as an injectable solution or powder for reconstitution, intended for intravenous and intramuscular administration
- It is used for the treatment of bacterial infections caused by susceptible microorganisms
- Teicoplanin holds approved status and is available in key regulatory markets
Clinical Overview
Clinically, teicoplanin is indicated for the treatment of infections caused by susceptible Gram-positive microorganisms. It exhibits a spectrum of activity comparable to vancomycin and is particularly useful for systemic bacterial infections. Oral formulations have demonstrated efficacy in the management of pseudomembranous colitis and Clostridium difficile-associated diarrhea.
Pharmacologically, teicoplanin acts by inhibiting bacterial cell wall synthesis. Specifically, it binds to the D-alanyl-D-alanine termini of peptidoglycan precursors, preventing polymerization. This mechanism disrupts cell wall integrity and ultimately leads to bacterial cell death.
Key pharmacokinetic parameters include administration typically via parenteral routes due to poor oral bioavailability, with a long elimination half-life enabling once-daily dosing in many cases. Tissue penetration and distribution align with other glycopeptide antibiotics, concentrating effectively in infected tissues.
Safety considerations include monitoring for hypersensitivity reactions and potential nephrotoxicity, as with other glycopeptides. The narrow therapeutic index of teicoplanin necessitates careful dosing and, in some cases, therapeutic drug monitoring to avoid toxicity while maintaining efficacy.
Teicoplanin is classified pharmacologically within amino acid derivatives, peptides, glycopeptide antibacterials, and anti-infective agents for systemic use. It is approved in various regulatory jurisdictions for clinical use, with ongoing investigational applications.
From an API sourcing perspective, consistent quality and purity are critical due to the structural heterogeneity of its components. Manufacturers should ensure rigorous analytical characterization of the composite mixture, control of impurities, and validation of manufacturing processes compliant with global regulatory standards. Stability and storage conditions must also be carefully managed to maintain API integrity.
Identification & chemistry
| Generic name | Teicoplanin |
|---|---|
| Molecule type | Small molecule |
| CAS | 61036-62-2 |
| UNII | 4U3D3YY81M |
| DrugBank ID | DB06149 |
Pharmacology
| Summary | Teicoplanin is a glycopeptide antibiotic that targets the D-Ala-D-Ala moiety of peptidoglycan precursor subunits, inhibiting bacterial cell wall synthesis. This action disrupts peptidoglycan polymerization, leading to bacterial cell death. It is active against susceptible gram-positive bacteria and is used in the treatment of bacterial infections, including those caused by Clostridium difficile. |
|---|---|
| Mechanism of action | Teicoplanin inhibits peptidoglycan polymerization, resulting in inhibition of bacterial cell wall synthesis and cell death. |
| Pharmacodynamics | It is a glycopeptide antiobiotic extracted from <i>Actinoplanes teichomyceticus</i>, with a similar spectrum of activity to vancomycin. Its mechanism of action is to inhibit bacterial cell wall synthesis. Oral teicoplanin has been demonstrated to be effective in the treatment of pseudomembranous colitis and Clostridium difficile-associated diarrhoea, with comparable efficacy to vancomycin. |
Targets
| Target | Organism | Actions |
|---|---|---|
| D-Ala-D-Ala moiety of NAM/NAG peptide subunits of peptidoglycan | Gram-positive Bacteria | inhibitor |
ADME / PK
| Absorption | Teicoplanin is poorly absorbed after oral administration but is 90% bioavailable when administered intramuscularly. |
|---|---|
| Half-life | 70-100 hours |
| Protein binding | 90% to 95% |
| Metabolism | Two metabolites (metabolites 1 and 2; 2 to 3% of total teicoplanin) have been isolated after intravenous administration of radiolabeled teicoplanin. After purification, their structures were found to be new teicoplanin-like molecules, bearing 8-hydroxydecanoic and 9-hydroxydecanoic acyl moieties. This metabolic transformation is likely due to hydroxylation in the omega-2 and omega-1 positions for metabolites 1 and 2, respectively, of the C-10 linear side chain of component A2-3. This might explain the low extent of metabolism of teicoplanin if we consider that only component A2-3 has a linear chain that is susceptible to such oxidation. |
Formulation & handling
- Teicoplanin is a small molecule antibiotic primarily formulated for parenteral use via intramuscular and intravenous injection.
- The API is available as a solid powder for solution and lyophilized injections, indicating the need for reconstitution prior to administration.
- Its low logP value (-2.3) suggests hydrophilic properties which may influence formulation solubility and stability profiles.
Regulatory status
Teicoplanin is a type of Glycopeptides
Glycopeptides are a subcategory of pharmaceutical active pharmaceutical ingredients (APIs) that play a crucial role in the field of medicinal chemistry and drug development. These complex molecules consist of a peptide chain with one or more attached carbohydrate chains, known as glycans.
Glycopeptides possess unique chemical and structural properties that contribute to their diverse biological activities. They are primarily recognized for their potent antimicrobial properties and are commonly used to combat various bacterial infections, including methicillin-resistant Staphylococcus aureus (MRSA) and other multidrug-resistant strains. This makes them highly valuable in the pharmaceutical industry.
The glycan moieties present in glycopeptides contribute to their mode of action. These carbohydrates aid in the recognition and binding of the glycopeptides to specific bacterial targets, inhibiting cell wall synthesis and disrupting bacterial growth. This mechanism of action sets glycopeptides apart from other classes of antibiotics, making them effective against resistant bacterial strains.
Glycopeptides can be produced through synthetic or semi-synthetic methods, with natural sources such as soil bacteria serving as starting materials. Vancomycin and teicoplanin are examples of well-known glycopeptide antibiotics. Researchers continue to explore the potential of glycopeptides in areas beyond antimicrobial applications, including cancer therapy and drug delivery systems.
In summary, glycopeptides represent a vital subcategory of pharmaceutical APIs with exceptional antimicrobial properties and significant potential in various therapeutic applications. Their complex structure and unique mechanism of action make them valuable assets in the fight against drug-resistant bacteria and other diseases.
Teicoplanin (Glycopeptides), classified under Antibacterials
Antibacterials, a category of pharmaceutical active pharmaceutical ingredients (APIs), play a crucial role in combating bacterial infections. These APIs are chemical compounds that target and inhibit the growth or kill bacteria, helping to eliminate harmful bacterial pathogens from the body.
Antibacterials are essential for the treatment of various bacterial infections, including respiratory tract infections, urinary tract infections, skin and soft tissue infections, and more. They are commonly prescribed by healthcare professionals to combat both mild and severe bacterial infections.
Within the category of antibacterials, there are different classes and subclasses of APIs, each with distinct mechanisms of action and target bacteria. Some commonly used antibacterials include penicillins, cephalosporins, tetracyclines, macrolides, and fluoroquinolones. These APIs work by interfering with various aspects of bacterial cellular processes, such as cell wall synthesis, protein synthesis, DNA replication, or enzyme activity.
The development and production of antibacterial APIs require stringent quality control measures to ensure their safety, efficacy, and purity. Pharmaceutical manufacturers must adhere to Good Manufacturing Practices (GMP) and follow rigorous testing protocols to guarantee the quality and consistency of these APIs.
As bacterial resistance to antibiotics continues to be a significant concern, ongoing research and development efforts aim to discover and develop new antibacterial APIs. The evolution of antibacterials plays a crucial role in combating emerging bacterial strains and ensuring effective treatment options for infectious diseases.
In summary, antibacterials are a vital category of pharmaceutical APIs used to treat bacterial infections. They are designed to inhibit or kill bacteria, and their development requires strict adherence to quality control standards. By continually advancing research in this field, scientists and pharmaceutical companies can contribute to the ongoing battle against bacterial infections.
Teicoplanin API manufacturers & distributors
Compare qualified Teicoplanin API suppliers worldwide. We currently have 8 companies offering Teicoplanin API, with manufacturing taking place in 4 different countries. Use the table below to review supplier type, countries of origin, certifications, product portfolio and GMP audit availability.
| Supplier | Type | Country | Product origin | Certifications | Portfolio |
|---|---|---|---|---|---|
| CKD Bio | Producer | South Korea | South Korea | CEP, CoA, GMP | 12 products |
| Dongkook Pharma | Producer | South Korea | South Korea | CEP, CoA, JDMF | 6 products |
| Flavine | Distributor | Germany | Unknown | CoA | 83 products |
| Gnosis Bioresearch S.R.L. | Producer | Italy | Italy | CEP, CoA, FDA, GMP, KDMF | 2 products |
| Sanofi | Producer | France | Unknown | CoA, GMP, JDMF | 93 products |
| Shaoxing Hantai Pharma | Distributor | China | China | CoA | 162 products |
| Sinoway industrial Co.,Lt... | Distributor | China | China | CEP, CoA, GMP, ISO9001, USDMF | 762 products |
| Socosur | Distributor | France | Unknown | CoA | 21 products |
When sending a request, specify which Teicoplanin API quality you need: for example EP (Ph. Eur.), USP, JP, BP, or another pharmacopoeial standard, as well as the required grade (base, salt, micronised, specific purity, etc.).
Use the list above to find high-quality Teicoplanin API suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our help page to learn more about sourcing APIs via Pharmaoffer.
